V. K. Gupta, R. Giri, and S. Agrawal, “Dipeptidyl peptidase-4 inhibitor (teneligliptin) significantly reduces liver fat content and delays progression of non-alcoholic steatohepatitis in type 2 diabetes mellitus patients”, Int J Adv Med, vol. 8, no. 12, pp. 1817–1820, Nov. 2021.